🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Georgia
Clinical trial register · United States · industry-sponsored

Clinical Trials in Georgia, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9119 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 25 Sep 2026, 03:16 UTC
9119
Studies in scope
industry-sponsored, all four open statuses
4952
Recruiting now
open to new participants
2205
Lead sponsors
across recruiting studies
Top states
California 5301 Florida 4401 Illinois 2480 Georgia 2350 Arizona 2233
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca104 Eli Lilly and Company87 Merck Sharp & Dohme LLC70 Janssen Research & Development, LLC67 AbbVie66
State
California5301 Florida4401 Illinois2480 Georgia2350 Arizona2233
All 51 states
Target enrolment
to

Trials with a site in Georgia

2350 of 9119 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Active, closed
Ph2 Open-label Study of AOC 1044 in Duchenne Muscular Dystrophy Participants With Mutations Amenable to Exon44 Skipping
NCT06244082DMD, Duchenne Muscular Dystrophy, Duchenne, Exon 44
DrugAOC 1044
Avidity Biosciences, Inc.
Phase 2
39
Arkansas, California, Georgia, Massachusetts, Minnesota, North Carolina, Ohio, Texas
2024-01-22
Active, closed
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
NCT06208150Multiple Myeloma
DrugsElotuzumab·Talquetamab·Teclistamab·Bortezomib
Janssen Research & Development, LLC
Phase 3
838
California, Connecticut, Delaware, Florida, Georgia, Idaho, Illinois, Iowa
2024-01-22
Recruiting
A Long Term, Post-marketing Study of Immune Response in Patients Receiving Palynziq Treatment for PKU (PALisade)
NCT06305234Phenylketonuria (PKU)
DrugPegvaliase
BioMarin Pharmaceutical
Observational
200
Colorado, Georgia, Illinois, Indiana, Louisiana, Massachusetts, Oregon, Pennsylvania
2024-01-20
Active, closed
Modification of Coronary Calcium With Laser Based Intravascular Lithotripsy for Coronary Artery Disease (FRACTURE)
NCT06181240Coronary Artery Disease, Coronary Artery Calcification
Bolt Medical
Not applicable
426
California, Colorado, Florida, Georgia, Massachusetts, Michigan, Minnesota, Mississippi
2024-01-19
Active, closed
A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies
NCT06120075Advanced Cancer
DrugPaclitaxel
Arcus Biosciences, Inc.
Phase 1
91
Colorado, District of Columbia, Georgia, Michigan, New York, Pennsylvania, Texas, Utah
2024-01-19
Active, closed
A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)
NCT06018337Metastatic Breast Cancer
DrugsDB-1303/BNT323·Nab-paclitaxel·Capecitabine·Paclitaxel
DualityBio Inc.
Phase 3
541
Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana, Kansas
2024-01-18
Active, closed
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
NCT06143878Plaque Psoriasis
DrugsIcotrokinra·Deucravacitinib
Janssen Research & Development, LLC
Phase 3
774
Arizona, Arkansas, California, Florida, Georgia, Illinois, Indiana, Kentucky
2024-01-17
Active, closed
GAE Using Embosphere Microspheres vs Corticosteroid Injections for Treatment of Symptomatic Knee OA (MOTION)
NCT05818150Knee Osteoarthritis
Merit Medical Systems, Inc.
Not applicable
264
California, District of Columbia, Georgia, Illinois, Massachusetts, Missouri, New Jersey, New York
2024-01-16
Recruiting
A Study of NST-6179 in Subjects With Intestinal Failure-Associated Liver Disease (IFALD).
NCT05919680Intestinal Failure Associated Liver Disease
NorthSea Therapeutics B.V.
Phase 2
36
Arizona, California, District of Columbia, Georgia, Illinois, Massachusetts, Michigan, Minnesota
2024-01-15
Active, closed
Study of ALXN2220 Versus Placebo in Adults With ATTR-CM
NCT06183931Transthyretin Amyloid Cardiomyopathy
DrugALXN2220
Alexion Pharmaceuticals, Inc.
Phase 3
1,181
California, Colorado, District of Columbia, Florida, Georgia, Illinois, Indiana, Massachusetts
2024-01-11
Recruiting
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
NCT06064877Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
DrugPemetrexed
AVEO Pharmaceuticals, Inc.
Phase 3
410
Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Illinois, Kansas
2024-01-11
Active, closed
LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF
NCT05983250Pulmonary Hypertension
DrugTNX-103
Tenax Therapeutics, Inc.
Phase 3
230
Arizona, California, Florida, Georgia, Illinois, Indiana, Kentucky, Massachusetts
2024-01-10
Active, closed
A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC
NCT05849298Prostatic Neoplasm
DrugsARPI·Pylarify·68Ga-PSMA-11·AAA617
Novartis Pharmaceuticals
Phase 2
49
Colorado, Georgia, Indiana, Iowa, Nebraska, Oregon, Pennsylvania, Texas
2024-01-03
Active, closed
Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)
NCT06098079Obesity
Currax Pharmaceuticals
Phase 4
8,600
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Indiana
2024-01-03
Recruiting
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
NCT06137118B-cell Acute Lymphoblastic Leukemia (B-ALL)
DrugSurovatamig
AstraZeneca
Phase 1/2
255
Alabama, California, Florida, Georgia, Illinois, New York, Texas, Virginia
2023-12-29
Active, closed
Pulsed Field Ablation (PFA) vs Anti-Arrhythmic Drug (AAD) Therapy as a First Line Treatment for Persistent Atrial Fibrillation
NCT06096337Persistent Atrial Fibrillation
Boston Scientific Corporation
Not applicable
484
Alabama, Arizona, Arkansas, California, Florida, Georgia, Illinois, Indiana
2023-12-28
Recruiting
Study of CTO1681 for the Prevention and Treatment of CRS in Patients Receiving CAR T-Cell Therapy
NCT05905328Cytokine Release Syndrome
CytoAgents, Inc.
Phase 1/2
54
California, Georgia, Massachusetts, North Carolina, Pennsylvania, Washington
2023-12-28
Recruiting
A Study to Investigate Efficacy and Safety of Pegtibatinase Compared With Placebo in Participants ≥12 to ≤65 Years of Age With Classical Homocystinuria (HCU) Due to Cystathionine Beta Synthase Deficiency Receiving Standard of Care Treatment
NCT06247085Homocystinuria
DrugPegtibatinase
Travere Therapeutics, Inc.
Phase 3
70
Arizona, Connecticut, Georgia, Illinois, Maine, Maryland, New York, North Carolina
2023-12-28
Recruiting
A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms
NCT06223880Major Depressive Disorder
DrugsDextromethorphan-bupropion·Bupropion
Axsome Therapeutics, Inc.
Phase 4
350
California, Florida, Georgia, Illinois, Kansas, Louisiana, Massachusetts, Missouri
2023-12-27
Active, closed
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
NCT06141486Multiple Sclerosis
DrugFrexalimab
Sanofi
Phase 3
943
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2023-12-27
Recruiting
BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT
NCT06059638Hypertension, Hypertension, Systolic, Hypertension, Essential
Orchestra BioMed, Inc
Not applicable
316
Arizona, California, Colorado, District of Columbia, Florida, Georgia, Idaho, Illinois
2023-12-27
Recruiting
A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC
NCT06010329Non-small Cell Lung Cancer
Teligene US
Phase 2
66
California, Florida, Georgia, Iowa, Kentucky, New York, Texas
2023-12-27
Active, closed
A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)
NCT06099782Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Melanoma
Drugs) Berahyaluronidase alfa·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 2
147
Alabama, Alaska, Arkansas, California, Florida, Georgia, Washington
2023-12-26
Recruiting
Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration
NCT06132035Age-related Wet Macular Degeneration
DrugsEylea·Aflibercept
Caregen Co. Ltd.
Phase 1
45
Connecticut, Florida, Georgia, Indiana, North Dakota, Pennsylvania
2023-12-22
Recruiting
A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
NCT06150157Neoplasms
DrugsMomelotinib·Ruxolitinib
Janssen Research & Development, LLC
Phase 1
300
California, Colorado, Florida, Georgia, Michigan, New Jersey, New York, North Carolina
2023-12-20
Recruiting
RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
NCT06154252Idiopathic Inflammatory Myopathy, Dermatomyositis, Anti-Synthetase Syndrome, Immune-Mediated Necrotizing Myopathy
Cabaletta Bio
Phase 2/3
74
California, Colorado, Florida, Georgia, Illinois, Kansas, Maryland, Massachusetts
2023-12-20
Recruiting
Observational Study Protocol: LIVER-R
NCT06252753Hepatobiliary Cancers
AstraZeneca
Observational
4,000
Alabama, Arizona, California, Florida, Georgia, Illinois, Louisiana, Massachusetts
2023-12-20
Recruiting
Contraceptive Efficacy Study of Ovaprene
NCT06127199Contraception
Daré Bioscience, Inc.
Not applicable
656
Arizona, California, Colorado, Georgia, Hawaii, Louisiana, Maryland, Massachusetts
2023-12-19
Active, closed
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo
NCT06118411Vitiligo
DrugUpadacitinib
AbbVie
Phase 3
614
Arizona, California, Florida, Georgia, Illinois, Indiana, Massachusetts, Michigan
2023-12-19
Recruiting
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
NCT06136650Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms
DrugsFludrocortisone acetate·Hydrocortisone·Opevesostat·Prednisone Acetate
Merck Sharp & Dohme LLC
Phase 3
1,314
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois
2023-12-18
Recruiting
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
NCT06170788Non-small Cell Lung Cancer (NSCLC)
DrugsSacituzumab tirumotecan·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
614
Arizona, California, Colorado, Florida, Georgia, Kentucky, Maine, Massachusetts
2023-12-15
Active, closed
A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma
NCT06084884Hepatocellular Carcinoma
DrugAZD5851
AstraZeneca
Phase 1/2
94
Arizona, California, District of Columbia, Florida, Georgia, Kansas, Minnesota, New Jersey
2023-12-14
Recruiting
MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
NCT06128629Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Intellia Therapeutics
Phase 3
1,200
Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois
2023-12-13
Active, closed
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
NCT06141473Multiple Sclerosis
DrugsTeriflunomide·Frexalimab
Sanofi
Phase 3
1,655
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2023-12-13
Active, closed
Real-World Effectiveness of Dupilumab in Patients With Prurigo Nodularis: An Observational Study
NCT05991323Prurigo Nodularis
DrugDupilumab
Sanofi
Observational
100
Arizona, California, Florida, Georgia, Indiana, Michigan, Missouri, Nebraska
2023-12-12
Active, closed
ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC
NCT05682443Metastatic Castration-resistant Prostate Cancer
OncoC4, Inc.
Phase 1/2
148
California, Colorado, Florida, Georgia, Maryland, Massachusetts, Mississippi, Nebraska
2023-12-11
Active, closed
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
NCT06065748Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
DrugsGiredestrant·Ribociclib·Abemaciclib·Palbociclib
Hoffmann-La Roche
Phase 3
1,050
Alabama, California, Colorado, District of Columbia, Florida, Georgia, Kentucky, Maine
2023-12-11
Active, closed
F15 Recharge Free Axonics SNM System Clinical Study
NCT06186765Urinary Urge Incontinence (UUI), Urinary Frequency (UF), Fecal Incontinence (FI)
Axonics, Inc.
Not applicable
144
Connecticut, Florida, Georgia, Minnesota, Nebraska, New York, Oregon, South Carolina
2023-12-08
Recruiting
Zenith® Fenestrated+ Clinical Study
NCT04875429Aortic Aneurysm, Abdominal, Juxtarenal Aortic Aneurysm, Extent IV Thoracoabdominal, Pararenal Aneurysm
Cook Research Incorporated
Not applicable
105
Alabama, California, District of Columbia, Florida, Georgia, Illinois, Indiana, Maryland
2023-12-08
Active, closed
A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines
NCT05976243Chronic Inducible Urticaria
DrugRemibrutinib
Novartis Pharmaceuticals
Phase 3
362
Alabama, Arkansas, California, Colorado, Florida, Georgia, Idaho, Illinois
2023-12-07
Active, closed
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
NCT06132958Endometrial Cancer
DrugsDoxorubicin·Sacituzumab tirumotecan·Nab-paclitaxel·Paclitaxel
Merck Sharp & Dohme LLC
Phase 3
710
Alabama, Alaska, Arizona, California, Connecticut, District of Columbia, Florida, Georgia
2023-12-06
Active, closed
Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)
NCT05769153Neovascular Age-related Macular Degeneration (nAMD)
DrugAflibercept
Alcon Research
Phase 1/2
139
Alabama, Arizona, California, Colorado, Connecticut, Florida, Georgia, Illinois
2023-12-06
Active, closed
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
NCT06077760Non-small Cell Lung Cancer
DrugsIntismeran autogene·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
868
Alaska, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Idaho
2023-12-06
Active, closed
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
NCT06007690Choroidal Melanoma, Indeterminate Lesions, Uveal Melanoma, Ocular Melanoma
Aura Biosciences
Phase 3
108
California, Florida, Georgia, Illinois, Massachusetts, Michigan, Minnesota, Missouri
2023-12-06
Recruiting
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
NCT06072612Breast Cancer, Metastatic Breast Cancer, Breast Neoplasm, Breast Cancer Metastatic
DrugsRetifanlimab·Cyclophosphamide
BriaCell Therapeutics Corporation
Phase 3
404
Arizona, California, Connecticut, Florida, Georgia, Illinois, Indiana, Kansas
2023-12-05
Recruiting
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
NCT06106945Multiple Myeloma
DrugsElranatamab·Pomalidomide·Dexamethasone
AstraZeneca
Phase 1/2
226
California, Georgia, Massachusetts, Michigan, Missouri, New York, Pennsylvania, Virginia
2023-12-05
Active, closed
Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
NCT06109779Biliary Tract Cancer
DrugsGemcitabine/Cisplatin·Rilvegostomig·Tegafur Gimeracil Oteracil·Capecitabine
AstraZeneca
Phase 3
760
Alabama, Arizona, California, Colorado, District of Columbia, Florida, Georgia, Illinois
2023-12-04
Active, closed
A Study of Efficacy and Safety of Rosnilimab in Subjects With Moderate to Severe Ulcerative Colitis (ROSETTA)
NCT06127043Ulcerative Colitis
DrugRosnilimab
AnaptysBio, Inc.
Phase 2
132
Arizona, California, Florida, Georgia, Illinois, Nevada, New York, Ohio
2023-12-04
Recruiting
Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Esophagus
NCT05561114Esophageal Stricture
GIE Medical
Phase 3
198
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas
2023-12-01
Recruiting
PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III
NCT05934487Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure
Endotronix, Inc.
Not applicable
1,750
Arizona, California, Florida, Georgia, Illinois, Indiana, Kansas, Maryland
2023-11-29
Active, closed
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)
NCT06113445NonSegmental Vitiligo
DrugPovorcitinib
Incyte Corporation
Phase 3
467
Alabama, California, Florida, Georgia, Indiana, Massachusetts, Michigan, Missouri
2023-11-29
By invitation
Evaluation of the GORE® Ascending Stent Graft
NCT05800743Aortic Aneurysm, Thoracic, Pseudoaneurysm, Aortic Dissection, Aorta; Lesion
W.L.Gore & Associates
Not applicable
370
Alabama, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Illinois
2023-11-28
Recruiting
Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
NCT06122077Lung Cancer Diagnosis
Freenome Holdings Inc.
Observational
20,000
California, Connecticut, Florida, Georgia, Illinois, Kansas, Maryland, Massachusetts
2023-11-28
Active, closed
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)
NCT06113471NonSegmental Vitiligo
DrugPovorcitinib
Incyte Corporation
Phase 3
450
Alabama, California, Florida, Georgia, Illinois, Indiana, Louisiana, Maryland
2023-11-27
Active, closed
A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer
NCT06116786Carcinoma, Non-small-Cell Lung
DrugsJNJ-86974680·Cetrelimab
Johnson & Johnson Enterprise Innovation Inc.
Phase 1
67
Georgia, New Jersey, New York, Oregon, Pennsylvania, Virginia
2023-11-27
Active, closed
A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease
NCT06154837Pulmonary Disease, Chronic Obstructive
DrugGSK3862995B
GlaxoSmithKline
Phase 1
127
Arizona, Florida, Georgia, North Carolina, Oregon, Pennsylvania, South Carolina, Texas
2023-11-27
Recruiting
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
NCT06103864Breast Cancer
DrugsDato-DXd·Durvalumab·Nab-paclitaxel·Gemcitabine
AstraZeneca
Phase 3
625
Alabama, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Hawaii
2023-11-23
By invitation
A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies
NCT06208878Hematologic Malignancy, Solid Malignancy
CRISPR Therapeutics AG
Observational
70
California, Connecticut, Georgia, Illinois, Kansas, Minnesota, Missouri, New York
2023-11-22
Recruiting
ALLIANCE AVIV: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve in Failing Aortic Bioprosthetic Valves
NCT05172973Aortic Valve Insufficiency, Aortic Valve Stenosis
Edwards Lifesciences
Not applicable
200
California, Colorado, Florida, Georgia, Illinois, Kansas, Maryland, Massachusetts
2023-11-22
Recruiting
A Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Participants With Influenza and Transmission of Influenza to Household Contacts
NCT06094010Influenza
DrugBaloxavir Marboxil
Hoffmann-La Roche
Phase 3
1,100
Alabama, Arkansas, Florida, Georgia, Idaho, Indiana, Kentucky, Louisiana
2023-11-22
Active, closed
Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
NCT06120491Metastatic Castration-Sensitive Prostate Cancer
DrugsSaruparib·Darolutamide·Abiraterone acetate·Enzalutamide
AstraZeneca
Phase 3
1,898
Arizona, Arkansas, California, Colorado, Connecticut, Georgia, Illinois, Indiana
2023-11-21
Active, closed
The PEERLESS II Study
NCT06055920Pulmonary Embolism
Inari Medical
Not applicable
1,200
Alabama, California, Colorado, Connecticut, Florida, Georgia, Illinois, Michigan
2023-11-17
Active, closed
Study of Lenacapavir and Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) in Prevention of HIV in Cisgender Women in the United States (HPTN 102)
NCT06101329Pre-Exposure Prophylaxis of HIV Infection
DrugsEmtricitabine/tenofovir disoproxil fumarate·F/TDF·Lenacapavir
Gilead Sciences
Phase 2
253
Alabama, California, District of Columbia, Georgia, Massachusetts, New Jersey, New York, North Carolina
2023-11-17
Active, closed
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
NCT06016738Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer
DrugsPalazestrant·Anastrozole·Exemestane·Letrozole
Olema Pharmaceuticals, Inc.
Phase 3
510
Arizona, California, Colorado, Connecticut, Delaware, Florida, Georgia, Illinois
2023-11-16
Active, closed
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.
NCT06063967Crohn's Disease
DrugRisankizumab
AbbVie
Phase 3
289
Arizona, California, Connecticut, Florida, Georgia, Idaho, Illinois, Indiana
2023-11-15
Active, closed
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis
NCT06136741Moderate to Severe Atopic Dermatitis
DrugRezpegaldesleukin
Nektar Therapeutics
Phase 2
396
Arkansas, California, Florida, Georgia, Indiana, Kentucky, Michigan, Nevada
2023-11-15
Recruiting
Efficacy of M640 in Acute Lumbosacral Musculoskeletal Conditions.
NCT06157177Sciatica Acute, Lumbar Spinal Stenosis
DrugMetaxalone
Primus Pharmaceuticals
Phase 4
50
Alabama, California, Florida, Georgia, Michigan, New Mexico, North Carolina, Ohio
2023-11-15
Active, closed
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
NCT06003231Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Endometrial Neoplasms, Head and Neck Neoplasms
DrugDisitamab Vedotin
Seagen, a wholly owned subsidiary of Pfizer
Phase 2
120
Arizona, California, Colorado, Connecticut, Florida, Georgia, Massachusetts, Michigan
2023-11-14
Active, closed
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
NCT06112379Breast Cancer
DrugsDato-DXd·Epirubicin·Olaparib·Doxorubicin
AstraZeneca
Phase 3
1,902
Alabama, Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia
2023-11-14
Active, closed
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
NCT06074588Non-small Cell Lung Cancer (NSCLC)
DrugsSacituzumab tirumotecan·Pemetrexed·Paclitaxel
Merck Sharp & Dohme LLC
Phase 3
556
California, Florida, Georgia, Michigan, Minnesota, Mississippi, Nebraska, New Jersey
2023-11-12
Active, closed
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
NCT06073821CLL
DrugsSonrotoclax·Zanubrutinib·Obinutuzumab·Venetoclax
BeOne Medicines
Phase 3
652
Alaska, California, Colorado, District of Columbia, Florida, Georgia, Illinois, Indiana
2023-11-11
Active, closed
A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
NCT06161571NASH/MASH, NAFLD/MASLD
DrugEfruxifermin
Akero Therapeutics, Inc
Phase 3
700
Alabama, Arizona, Arkansas, California, Colorado, Florida, Georgia, Indiana
2023-11-10
Active, closed
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
NCT06097728Unresectable Pleural Mesothelioma
DrugsVolrustomig·Ipilimumab·Nivolumab·Pemetrexed
AstraZeneca
Phase 3
863
California, Colorado, Florida, Georgia, Illinois, Minnesota, Missouri, New York
2023-11-09
Active, closed
A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2
NCT06072183Stable Nonsegmental Vitiligo, Active Nonsegmental Vitiligo
DrugRitlecitinib
Pfizer
Phase 3
1,571
Arizona, Arkansas, California, Florida, Georgia, Illinois, Indiana, Maryland
2023-11-08
Recruiting
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
NCT06014658Cancer
MBrace Therapeutics
Phase 1/2
130
California, Colorado, Georgia, Illinois, Indiana, Michigan, Nevada, New Jersey
2023-11-07
Active, closed
Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)
NCT06087835Chronic Kidney Disease With High Proteinuria
DrugDapagliflozin
AstraZeneca
Phase 3
1,835
Alabama, Arizona, California, Colorado, Florida, Georgia, Illinois, Kentucky
2023-11-07
Active, closed
Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.
NCT05782907Ulcerative Colitis
DrugUpadacitinib
AbbVie
Phase 3
122
Arizona, Arkansas, California, Colorado, Delaware, Georgia, Illinois, Massachusetts
2023-11-06
Active, closed
A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations
NCT06101134Melanoma
DrugsRHuPH20·Relatlimab·Nivolumab
Bristol-Myers Squibb
Phase 2
100
Alaska, Arizona, California, Georgia, Kentucky, New Mexico, Washington
2023-11-06
By invitation
Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy
NCT06066580Becker Muscular Dystrophy
Edgewise Therapeutics, Inc.
Phase 2
260
Arkansas, California, Colorado, Florida, Georgia, Illinois, Indiana, Iowa
2023-11-02
Recruiting
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
NCT05862012Relapsed/Refractory Multiple Myeloma
Ichnos Sciences SA
Phase 1
200
California, Florida, Georgia, Illinois, Massachusetts, New York, North Carolina, Tennessee
2023-11-01
Recruiting
A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
NCT06095089Prostatic Neoplasms
DrugsJNJ-101556143·Lutetium Lu-177 vipivotide tetraxetan·JNJ-87189401·Pasritamig
Janssen Research & Development, LLC
Phase 1
355
Colorado, Georgia, Minnesota, New Jersey, New York, North Carolina, Oregon, Pennsylvania
2023-11-01
Recruiting
Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Bowel
NCT05561127Bowel; Stricture
GIE Medical
Phase 3
171
Arizona, California, Colorado, Florida, Georgia, Illinois, Kansas, Kentucky
2023-11-01
Active, closed
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
NCT05987332Metastatic Uveal Melanoma
DrugsIDE196·Dacarbazine·Crizotinib·Ipilimumab
IDEAYA Biosciences
Phase 2/3
420
Arizona, California, Colorado, Florida, Georgia, Iowa, Massachusetts, Michigan
2023-10-31
Recruiting
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
NCT05696626Metastatic Breast Cancer
DrugsAbemaciclib·Fulvestrant
LeonaBio
Phase 3
600
Arizona, California, Florida, Georgia, Kentucky, Maryland, Massachusetts, Michigan
2023-10-31
Recruiting
Prospective Multi-Center Trial for FemBloc Permanent Birth Control
NCT05977751Contraception
Femasys Inc.
Not applicable
573
Arizona, California, Georgia, Idaho, New York, Ohio, Tennessee, Utah
2023-10-31
Recruiting
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
NCT05943535Progressive Pulmonary Fibrosis, Interstitial Lung Disease
DrugTreprostinil
United Therapeutics
Phase 3
698
Alabama, Arizona, California, District of Columbia, Florida, Georgia, Illinois, Kansas
2023-10-30
Recruiting
VALOR: Vaginal Atrophy & Long-term Observation of Recovery
NCT05953090Atrophic Vaginitis, Vaginal Atrophy, Genitourinary Syndrome of Menopause, Lichen Sclerosus of Vulva
Stratpharma AG
Not applicable
2,000
Alabama, California, Florida, Georgia, Nevada, North Carolina, South Carolina, Tennessee
2023-10-30
Active, closed
A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.
NCT05985915Sjogrens Syndrome
DrugIanalumab
Novartis Pharmaceuticals
Phase 3
612
California, Florida, Georgia, Illinois, Kansas, Louisiana, Maryland, Massachusetts
2023-10-27
Active, closed
Gravitas Feeding Tube System Placement Validation in Neonates
NCT05914064Nasogastric Tube
Gravitas Medical, Inc.
Not applicable
100
California, Georgia, Massachusetts, Rhode Island, Virginia
2023-10-27
Recruiting
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
NCT05899608Non-Small Cell Lung Cancer
DrugsPembrolizumab·Bevacizumab
Summit Therapeutics
Phase 3
1,600
Arizona, Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois
2023-10-26
Recruiting
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
NCT06119685NHL, Multiple Myeloma, Blood Cancer, Refractory Non-Hodgkin Lymphoma
DrugsMesna·Isatuximab·IL-2·Daratumumab
Indapta Therapeutics, INC.
Phase 1/2
128
California, Florida, Georgia, Minnesota, New York, North Carolina, Ohio, Oregon
2023-10-25
By invitation
Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients
NCT06126380Kidney Transplant Rejection
DrugsAT-1501·Tacrolimus
Eledon Pharmaceuticals
Phase 2
132
California, District of Columbia, Florida, Georgia, Illinois, Kansas, Louisiana, Maryland
2023-10-25
Recruiting
Nectero EAST System Clinical Study
NCT06001918Abdominal Aortic Aneurysm
Nectero Medical, Inc.
Phase 2/3
400
Arizona, Colorado, District of Columbia, Florida, Georgia, Illinois, Maine, Massachusetts
2023-10-25
Active, closed
A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)
NCT06052059Ulcerative Colitis
DrugTulisokibart
Merck Sharp & Dohme LLC
Phase 3
1,020
Alabama, Arizona, California, Colorado, Connecticut, District of Columbia, Florida, Georgia
2023-10-25
Active, closed
RESOLVE-AF: Clinical Evaluation of the Ablacath™ Mapping Catheter and Ablamap® System Utilizing Electrographic Flow (EGF) Mapping to Resolve Extra-PV Sources of Atrial Fibrillation and Guide Ablation Therapy.
NCT05883631Atrial Fibrillation, Atrial Fibrillation, Persistent, Atrial Fibrillation Paroxysmal, Arrhythmia
Cortex
Not applicable
400
Alabama, Arizona, California, Colorado, Florida, Georgia, Michigan, New York
2023-10-23
Active, closed
SELUTION 4 De Novo Small Vessel IDE Trial
NCT05946629Coronary Artery Disease
M.A. Med Alliance S.A.
Not applicable
960
Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Hawaii
2023-10-20
Active, closed
Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischemic NYHA Class III Heart Failure
NCT05598333Congestive Heart Failure
AskBio Inc
Phase 2
150
Alabama, Arizona, California, Florida, Georgia, Illinois, Iowa, Kansas
2023-10-20
Active, closed
Safety and Tolerability of GTX-104 Compared with Oral Nimodipine in Patients with ASAH
NCT05995405Aneurysmal Subarachnoid Hemorrhage (aSAH)
Grace Therapeutics Inc.
Phase 3
100
Alabama, Arizona, California, Florida, Georgia, Illinois, Indiana, Kentucky
2023-10-20
Active, closed
Nerve Protection Evaluation: Revision Cubital Tunnel Syndrome Decompression
NCT06117501Recurrent Cubital Tunnel Syndrome, Recalcitrant Cubital Tunnel Syndrome
Axogen Corporation
Not applicable
20
Florida, Georgia, Indiana, New Mexico, Ohio, Pennsylvania, Utah
2023-10-19
Recruiting
The GORE VBX FORWARD Clinical Study: A Comparison of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis to Bare Metal Stenting for Patients With Complex Iliac Occlusive Disease
NCT05811364Aortoiliac Occlusive Disease, Peripheral Arterial Disease
W.L.Gore & Associates
Not applicable
244
Arkansas, California, Colorado, Florida, Georgia, Louisiana, Massachusetts, Michigan
2023-10-17
Rows per page Showing 1301–1400 of 2350
Previous 12 13 14 15 16 Next
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-usa/state/georgia?page=14

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,119 studies in total at the last sync on 25 Sep 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 2,350 of those studies with a site in Georgia.

How many clinical trials are recruiting in Georgia?

1,212 of the 2,350 studies on this page are recruiting new participants as of the 25 Sep 2026, 03:16 UTC sync. A further 40 have not yet opened recruitment, 1,038 are active but closed to new participants, and 60 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.